The introduction of β-adrenoceptor antagonists in the treatment of congestive heart failure

Bibliography

• PACKER M. Survival in patients with chronic heart failure and its potential modification by drug therapy. In: Drug Treatment in Heart Failure. Cohn JN, Secaucus NJ (Eds.), ATC International, NewYork (1988):273.
   Google Scholar
• FRANCIS GS: Determinants of prognosis in patients with heart failure [Review]. I Heart Lung Transplant. (1994) 13:S113–S116.
   PubMed Web of Science ®Google Scholar
• DEEDWANIA PC: Prevalence and prognosis of heart failure [Review]. Cardiol. Clin. (1994) 12:1–8.
   PubMedGoogle Scholar
• COHN JN: Has the problem of heart failure been solved [Review]. Am. I Cardiol. (1994) 73:40C-43C.
   Google Scholar
• ARMSTRONG PW, MOE GW: Medical advances in the treatment of congestive heart failure [Review]. Circulation (1993) 88:2941–2952.
   PubMed Web of Science ®Google Scholar
• HO KKL, PINSKY JL, KANNEL WB, LEVY D: The epidemiology of heart failure: the Framing- ham study. 1 Am. Coll. Cardiol. (1993) 22(Suppl. A):6A-13A.
   Google Scholar
• PACKER M, BRISTOW MR, COHN IN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl. I Med. (1996) 334:1349–1355.
   PubMed Web of Science ®Google Scholar
• THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl. I Med. (1997) 338:525–532.
   Web of Science ®Google Scholar
• TOWNEND JN, LITTLER WA: Angiotensin converting enzyme inhibitors in heart failure: how good are they Br. Heart. J. (1993) 69:373–375.
   Web of Science ®Google Scholar
• JOHNSTON CI, FABRIS B, YOSHIDA K: The cardiac renin-angiotensin system in heart failure [Review]. Am. Heart J. (1993) 126:756–760.
   PubMed Web of Science ®Google Scholar
• LECHAT P, GARNHAM SP, DESCHE P, BOUNHOURE JP: Efficacy and acceptability of perin-dopril in mild to moderate chronic congestive heart failure. Am. Heart J. (1993) 126:798–806.
   PubMed Web of Science ®Google Scholar
• REID JL, MACFADYEN RJ, SQUIRE IB, LEES KR: Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. Am. Heart 1 (1993) 126:794–797.
   Google Scholar
• EICHHORN EJ, SOBOTKA P: Novel approaches to congestive heart failure - use of beta-adren-ergic blockade. Coronary Artery. Dis. (1994) 5:101–106.
   PubMed Web of Science ®Google Scholar
• GILBERT EM, SANDOVAL A, LARRABEE P, et al.: Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart. Circulation (1993) 88:472–480.
   PubMedGoogle Scholar
• BRODDE OE, ADAMCZYK M, BUSCH F, et al.: Selective down-regulation of rat cardiac beta 1-adrenoceptors by cyclosporine A: prevention by diltiazem or angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. (1995) 25:761–767.
   PubMed Web of Science ®Google Scholar
• BRILLA CG, RUPP H, FUNCK R, MAISCH B: The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur. Heart J. (1995) 16:107–109.
   PubMedGoogle Scholar
• DHALLA NS, AFZAL N, BEAMISH RE, et al.: Pathophysiology of cardiac dysfunction in congestive heart failure [Review]. Can. 1 Cardiol. (1993) 9:873–887.
   Google Scholar
• YOUNG JB: Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials [Review]. Eur. Heart 1 (1993) 14(Suppl. C): 14–17.
   Google Scholar
• JOHNSTON CI, FABRIS B, YOSHIDA K: The cardiac renin-angiotensin system in heart failure [Review]. Am. Heart J. (1993) 126:756–760.
   PubMed Web of Science ®Google Scholar
• SHIMIZU K, MCGRATH BP: Sympathetic dysfunction in heart failure [Review]. Baillieres Clin. Endocrinol. Metab. (1993) 7:439–463.
   PubMed Web of Science ®Google Scholar
• CODY RJ: Optimising ACE inhibitor therapy of congestive heart failure. Insights from pharma-codynamic studies [Review]. Clin. Pharmacokinet. (1993) 24:59–70.
   PubMedGoogle Scholar
• COHN IN, LEVINE TB, OLIVARI MT, et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl. I Med. (1984) 311:819–823.
   PubMed Web of Science ®Google Scholar
• BRODDE OE, DAUL A, MICHEL MC, ZERKOWSKI HR: [Importance of beta 2-adrenergic receptors in heart failure]. Z. Kardiol. (1992) 81\(Suppl. 4):71–78.
   PubMedGoogle Scholar
• BRODDE OE, ZERKOWSKI HR, DOETSCH N, et al.: Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta 1- and beta 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. J. Am. Coll. Cardiol. (1989) 14:323–331.
   PubMed Web of Science ®Google Scholar
• BRODDE OE: Chronic beta 1-blocker treatment and cardiac beta 2-adrenoceptor function [Letter]. Am. Heart J. (1992) 123:1727–1728.
   PubMedGoogle Scholar
• BRODDE OE, ZERKOWSKI HR, BORST HG, MAIER W, MICHEL MC: Drug-and disease-in-duced changes of human cardiac beta-1 and beta-2 adrenoceptors. Eur. Heart J. (1989) 10(Suppl. B):38–44.
   PubMedGoogle Scholar
• BRISTOW MR, GINSBURG R, UMANS V, et al.: Beta 1-and beta 2-adrenergic-receptor subpopu-lations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ. Res. (1986) 59:297–309.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, KANTROWITZ NE, GINSBURG R, FOWLER MB: Beta-adrenergic function in heart muscle disease and heart failure. J. Mol. Cell Cardiol. (1985) 17\(Suppl. 2):41–52.
   PubMedGoogle Scholar
• PETCH MC, NAYLER WG: Uptake of catecholamines by human cardiac muscle in vitro. Br. Heart J. (1979) 41:336–339.
   PubMedGoogle Scholar
• BOHM M, LA ROSEE K, SCHWINGER RHG, ERDMANN E: Evidence for reduction of no-repinephrine uptake sites in the failing human heart. I Am. Coll. Cardiol. (1995) 25:146–153.
   PubMed Web of Science ®Google Scholar
• KLINGENHEBEN T, HOHNLOSER SH: Heart rate variability before and after beta-receptor blockade with sotalol. Z. Kardiol. (1994) 83:293–298.
   PubMedGoogle Scholar
• VISKIN S, KITZIS 1, LEV E, et al.: Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J. Am. Coll. Cardiol. (1995) 1282:7689–7711.
   Google Scholar
• NEUBAUER GE, GAUDRON P, HORN M, et al.: Beta-blockers in cardiac failure [Review]. Eur. Heart J. (1994) 15(Suppl. C):16–24.
   Google Scholar
• SOBOTKA PA, GUNNAR RM: The use of beta-blockade therapy in treatment of congestive heart failure [Review]. Clin. Cardiol. (1992) 15:630–635.
   PubMed Web of Science ®Google Scholar
• PANFILOV V, WAHLQVIST I, OLSSON G: Use of beta-adrenoceptor blockers in patients with congestive heart failure [Review]. Cardiovasc. Drugs Ther. (1995) 9:273–287.
   PubMed Web of Science ®Google Scholar
• KRUM H, SACKER-BERNSTEIN JD, GOLDSMITH RL, et al.: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation (1995) 92:1499–1506.
   PubMedGoogle Scholar
• AHLQUIST RP: A study of the adrenotropic receptors. Am. I Physiol. (1948) 153:586–600.
   PubMed Web of Science ®Google Scholar
• LANDS AM, ARNOLD A, MCAULIFF JP, LUDUENA FP, BROWN TG: Differentiation of receptor systems activated by sympathomimetic amines. Nature (1967) 214:597–598.
   PubMedGoogle Scholar
• SUMMERS RJ, MOLENAAR P, STEPHENSON JA: Autoradiographic localization of receptors in the cardiovascular system. Trends Pharmacol. Sci. (1987) 8:272–276.
   Web of Science ®Google Scholar
• FREISSMUTH M, HAUSLEITHNER V, NEES S, BOCK M, SCHUTZ W: Cardiac ventricular beta 2-adrenoceptors in guinea-pigs and rats are localized on the coronary endothelium. Naunyn-Schmiedeberg's Arch. Pharmacol. (1986) 334:56–62.
   Google Scholar
• MOLENAAR P, JONES CR, MCMARTIN LR, SUMMERS RJ: Autoradiographic localization and densitometric analysis of beta-1 and beta-2 adrenoceptors in the canine left anterior descending coronary artery. J. Pharmacol. Exp. Ther. (1988) 246:384–393.
   PubMed Web of Science ®Google Scholar
• BRODDE OE: Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev. (1991) 43:203-242. [Published erratum appears in Pharmacol. Rev. (1991) 43(3):3501.1
   PubMedGoogle Scholar
• FRIELLE T, COLLINS S, DANIEL KW, et al.: Cloning of the cDNA for the human beta 1-adren-ergic receptor. Proc. Natl. Acad. Sci. USA (1987) 84:7920–7924.
   PubMed Web of Science ®Google Scholar
• KOBILKA BK, DIXON RA, FRIELLE T, et al.: cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc. Natl. Acad. Sci. USA (1987) 84:46–50.
   PubMed Web of Science ®Google Scholar
• DIXON RA, KOBILKA BK, STRADER DJ, et al.: Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature (1986) 321:75–79.
   PubMedGoogle Scholar
• EMORINE LJ, MARULLO S, BRIEND-SUTREN MM, et al.: Molecular characterization of the human beta 3-adrenergic receptor. Science (1989) 245:1118–1121.
   PubMed Web of Science ®Google Scholar
• ZAAGSMA J, NAHORSKI SR: Is the adipocyte beta-adrenoceptor a prototype for the recently cloned atypical 'beta 3-adrenoceptor' [Review]. Trends Pharmacol. Sci. (1990) 11:3–7.
   PubMedGoogle Scholar
• SIMON MI, STRATHMANN MP, GAUTAM N: Diversity of G proteins in signal transduction [Review]. Science (1991) 252:802–808.
   PubMed Web of Science ®Google Scholar
• BENOVIC JL, STRASSER RH, CARON MG, LEFKOWITZ RJ: 13-Adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc. Natl. Acad. Sci. USA (1986) 83:2797–2801.
   PubMed Web of Science ®Google Scholar
• BENOVIC JL, PIKE LJ, CERIONE RA, et al.: Phosphorylation of the mammalian 13-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phospho-rylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J. Biol. Chem. (1985) 260:7094–7101.
   PubMed Web of Science ®Google Scholar
• LOHSE MJ, BENOVIC JL, CODINA J, CARON MG, LEFKOWITZ RJ: 6-Arrestin, a protein that regulates 13-adrenergic receptor function. Science (1990) 248:1547–1550.
   PubMedGoogle Scholar
• BENOVIC JL, KUHN H, WEYAND I, et al.: Functional desensitization of the isolatedp-adrenergic receptor by the 13-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48 kDa protein). Proc. Natl. Acad. Sci. USA (1987) 84:8879–8882.
   PubMed Web of Science ®Google Scholar
• BOUVIER M, COLLINS S, O'DOWD BF, et al.: Two distinct pathways for cAIVIP-mediated down-regulation of the beta 2-adrenergic receptor. Phosphorylation of the receptor and regula-tion of its mRNA level. J. Biol. Chem. (1989) 264:16786–16792.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, HERSHBERGER RE, PORT JD, MINOBE W, RASMUSSEN R: Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing humanventricular myocardium. Mol. Pharmacol. (1989) 35:295–303.
   PubMed Web of Science ®Google Scholar
• FELDMAN AM, GATES AE, VEAZEY WB: Increase of the Mr 40,000 pertussis toxin substrate (G protein) in the failing human heart. J. Clin. Invest. (1988) 82:189–197.
   PubMed Web of Science ®Google Scholar
• FELDMAN AM, JACKSON DG, BRISTOW MR, CATES AE, VAN DOP C: Immunodetectable levels of the inhibitory guanine nucleotide binding proteins in failing human heart: discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate. J. MoL Cell. CardioL (1991) 23:439–452.
   PubMed Web of Science ®Google Scholar
• NEUMANN J, SCHMITZ W, SCHOLZ H, et al: Increase in myocardial Gi proteins in heart failure. Lancet (1988) 22:936–937.
   Google Scholar
• ESCHENHAGEN T, MENDE U, NOSE M: Increased messenger RNA level of the inhibitory Ga-protein-subunit Gioc_2 in human end-stage heart failure. Circ. Res. (1992) 70:688–696.
   PubMed Web of Science ®Google Scholar
• BOHM M, ESCHENHAGEN T, GIERSCHIK P: Radioimmunochemical quantification of Gi in right and left ventricles of patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J. MoL Cell. CardioL (1994) 26:133–149.
   PubMed Web of Science ®Google Scholar
• WHITE M, RODEN R, MINOBE W, et al.: Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation (1994) 90:1225–1238.
   PubMed Web of Science ®Google Scholar
• UNGERER M, BOHM M, ELCE JS, ERDMANNE, LOHSE MJ: Altered expression of beta-adren-ergic receptor kinase and beta 1-adrenergic receptors in the failing human heart [see comments]. Circulation (1993) 87:454–463.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, MINOBE W, RASMUSSEN R, et al.: Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J. Clin. Invest. (1992) 89:803–815.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA T, PORT JD, ASANO K, et al.: Cardiac adrenergic receptor effects of carvedilol. Eur. Heart J. (1996) 17(Suppl. B):8–16.
   PubMedGoogle Scholar
• RUFFOLO RR, BONDINELL WE, HIEBLE JP: Alpha-and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J. Med. Chem. (1995) 38(19):3681–3716.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, BONDINELL WE, RUFFOLO RR: Alpha-and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. I Med. Chem. (1995) 38(18.):3415–3444.
   Web of Science ®Google Scholar
• WAAGSTEIN F, HJALMARSON A, VARNAUSKAS E: Effect of chronic 13-adrenergic blockade in congestive cardiomyopathy. Br. Heart J. (1975) 37:1022–1036.
   PubMedGoogle Scholar
• CURRIE PJ, KELLY MJ, MCKENZIE A, et al.: Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J. Am. Coll. CardioL (1984) 3:203–209.
   PubMed Web of Science ®Google Scholar
• IKRANI H, FITZPATRICK D: Double-blind trial of chronic oral beta-blockade in congestive cardiomyopathy. Lancet (1981) 2:490–492.
   Web of Science ®Google Scholar
• PRICHARD BN: Carvedilol in ischaemic heart disease [Review]. Cardiology (1993) 82(Suppl. 3):34–39.
   Google Scholar
• WAAGSTEIN F: Beta blockers in heart failure [Review]. Cardiology (1993) 82\(Suppl. 3):13–18.
   PubMedGoogle Scholar
• FOWLER MB: Controlled trials with beta blockers in heart failure: metoprolol as the prototype [Review]. Am. I Cardiol. (1993) 71:45C-53C.
   PubMedGoogle Scholar
• A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees [see comments]. Circulation (1994) 90:1765–1773.
   PubMed Web of Science ®Google Scholar
• CHIDSEY CA, HARRISON DC, BRAUNVVALD E: Augmentation of the plasma noradrenaline response to exercise in patients with congestive heart failure. New Engl. J. Med. (1962) 267:650–654.
   PubMedGoogle Scholar
• BRISTOW MR, GINSBURG R, MINOBE W, et al.: Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. New Engl. I Med. (1982) 307:205–211.
   PubMed Web of Science ®Google Scholar
• ANDERSSON B, BLOMSTROM LUNDQVIST C, HEDNER T, WAAGSTEIN F: Exercise hemody- namics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure [see comments]. J. Am. Coll. CardioL (1991) 18:1059–1066.
   PubMed Web of Science ®Google Scholar
• ASSEMAN P, MCFADDEN E, BAUCHART JJ, LOUBEYRE C, THERY C: Why do beta-blockers help in idiopathic dilated cardiomyopathy - frequency mismatch Lancet (1994) 344:803–804.
   PubMed Web of Science ®Google Scholar
• WAAGSTEIN F, CAIDAHL K, WALLENTIN I, BERGH C-H, HJALMARSON A: Long-term beta-blockade in congestive cardiomyopathy. Effects of acute and chronic metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation (1989) 80:551–563.
   PubMed Web of Science ®Google Scholar
• YATES JC, BEAMISH RE, DHALLA NS: Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine. Relation to pathogenesis of catecholamine cardiomyopathy. Am. Heart J. (1981) 102:210–221.
   PubMedGoogle Scholar
• FOWLER MB: Beta-blockers in heart failure: potential of carvedilol. J. Human Hypertens. (1993) 7\(Suppl. 1):562–567.
   Google Scholar
• ABLAD B, BJURO T, BJORKMAN J-A, EDSTROM T, OLSSON G: Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone. J. Am. Coll. Cardiol. (1991) 17:165.
   Web of Science ®Google Scholar
• MAGNUSSON Y, WALLUKAT A, WAAGSTEIN F, HJALMARSON A, HOEBEKE J: Autoimmu- nity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation (1994) 89:2760–2767.
   PubMed Web of Science ®Google Scholar
• MAISEL AS: Treatment of heart failure with metoprolol: beneficial immunologic effects. Circu- lation (1993) 88(Suppl. I):1105.
   Google Scholar
• WALLUKAT G, MORWINSKI M, KOWAL M, et al.: Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrenergic agonism without desensitization. Eur. Heart J. (1991) 12(Suppl. D):178–181.
   Google Scholar
• INSEL PA, RANSAS LA: G-proteins and cardiovascular disease. Circulation (1988) 78:1503–1511.
   Google Scholar
• VAN ZWIETEN PA: Changing insights in the drug treatment of congestive heart failure. Exp.Opin. Invest. Drugs (1995) 4(11):1045–1056.
   Google Scholar